CVE Explorer
CVE-2026-21974
Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data. CVSS 3.1 Base Score
Known exploited
Not asserted
Disputed
No
Stale source
No
Conflicts
1
Preserved source conflicts
No provider value was silently selected as the winner.
cwe · 2 assertions
{"description":"Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data.","lang":"en-US"}
- cve_program_cvelist_v5cweurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/cna/problemTypes/0/descriptions/0
{"cweId":"CWE-200","description":"CWE-200 Exposure of Sensitive Information to an Unauthorized Actor","lang":"en","type":"CWE"}
- cve_program_cvelist_v5cweurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/adp/0/problemTypes/0/descriptions/0
Affected products and versions
1 source assertion{"product":"Oracle Life Sciences Central Designer","vendor":"Oracle Corporation","versions":[{"status":"affected","version":"7.0.1.0","versionType":"semver"}]}
- cve_program_cvelist_v5affectedurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/cna/affected/0
Provider-owned CVSS observations
1 source assertion{"metric":{"attackComplexity":"LOW","attackVector":"NETWORK","availabilityImpact":"NONE","baseScore":5.3,"baseSeverity":"MEDIUM","confidentialityImpact":"LOW","integrityImpact":"NONE","privilegesRequired":"NONE","scope":"UNCHANGED","userInteraction":"NONE","vectorString":"CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N","version":"3.1"},"metric_type":"cvssV3_1"}
- cve_program_cvelist_v5cvssurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/cna/metrics/0/cvssV3_1
CWE assertions
2 source assertions{"description":"Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data.","lang":"en-US"}
- cve_program_cvelist_v5cweurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/cna/problemTypes/0/descriptions/0
{"cweId":"CWE-200","description":"CWE-200 Exposure of Sensitive Information to an Unauthorized Actor","lang":"en","type":"CWE"}
- cve_program_cvelist_v5cweurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/adp/0/problemTypes/0/descriptions/0
Source references
1 source assertion{"name":"Oracle Advisory","tags":["vendor-advisory"],"url":"https://www.oracle.com/security-alerts/cpujan2026.html"}
- cve_program_cvelist_v5referenceurn:baitaphish:normalized-source-record:v2:fc50b20590f499f0814f35e8a9f8717456ae81d1fbccf29fdb5060cffc3bc0a9 · sha256:c930c6ec3835c538… · /containers/cna/references/0
Attribution and limitations
- CVE Program CVEList V5: Reproduce the MITRE copyright designation and CVE license in copies. Source →
Provider severity values are preserved separately. Baitaphish does not convert them into a risk rating, infer affected products, or treat EPSS as observed exploitation.